<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974896</url>
  </required_header>
  <id_info>
    <org_study_id>20060134</org_study_id>
    <secondary_id>QUILT-2.016</secondary_id>
    <nct_id>NCT00974896</nct_id>
  </id_info>
  <brief_title>QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NantCell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NantCell, Inc.</source>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in&#xD;
      combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects&#xD;
      with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo&#xD;
      cohorts are enrolling. All other combo cohorts are closed to enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib or gemcitabine in subjects with advanced solid tumors</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacokinetic (PK) profiles of biologics or chemotherapy when used in combination with AMG 479</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumor response as assessed by World Health Organization (WHO) criteria</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumor response as measured by volumetric computed tomography (CT)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate anti-AMG 479 antibody response following AMG 479 administration</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>AMG 479 + Sorafenib cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 479 + Erlotinib cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 479</intervention_name>
    <description>AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).</description>
    <arm_group_label>AMG 479 + Erlotinib cohorts</arm_group_label>
    <arm_group_label>AMG 479 + Sorafenib cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved&#xD;
             informed consent form&#xD;
&#xD;
          -  Men and women ≥ 18 years old with a pathologically or cytologically documented,&#xD;
             advanced solid tumor that is refractory to at least one line of therapy or for whom no&#xD;
             standard therapy is available and for which no curative therapy is available, or the&#xD;
             subject refuses standard non-curative therapy&#xD;
&#xD;
          -  Measurable disease or evaluable disease per World Health Organization (WHO) guidelines&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy of 3 months as documented by the investigator&#xD;
&#xD;
          -  Adequate hematologic, renal and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any co-morbid medical condition that would increase the risk of toxicity in the&#xD;
             opinion of Investigator or Sponsor&#xD;
&#xD;
          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved&#xD;
             to Common Terminology Criteria for Adverse Events (CTCAE) grade 0 or 1, or to levels&#xD;
             dictated in the inclusion/exclusion criteria with the exception of alopecia&#xD;
&#xD;
          -  Subjects with primary or metastatic central nervous system (CNS) tumors are not&#xD;
             allowed to enroll in the sorafenib cohorts. These subjects are allowed to enroll in&#xD;
             the remaining cohorts, only if their CNS tumors have been controlled by prior surgery&#xD;
             or radiation, and they have been neurologically stable&#xD;
&#xD;
          -  History of lymphoma, leukemia, or high-dose chemotherapy with hematopoietic stem cell&#xD;
             rescue&#xD;
&#xD;
          -  Uncontrolled hypertension [diastolic &gt;100 mmHg or systolic &gt;150 mmHg]; Subjects&#xD;
             enrolling in the sorafenib groups must not have diastolic &gt; 85 mmHg nor systolic &gt; 145&#xD;
             mmHg&#xD;
&#xD;
          -  Clinically significant ECG changes which obscure the ability to assess the PR, QT, QRS&#xD;
             intervals&#xD;
&#xD;
          -  Presence of ascites or pleural effusion requiring chronic medical intervention&#xD;
&#xD;
          -  Diagnosis of arterial or venous thrombosis within 6 months before enrollment; history&#xD;
             of bleeding diathesis&#xD;
&#xD;
          -  History of clinically significant hypoglycemia or hyperglycemia in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Myocardial infarction within 6 months before enrollment, symptomatic congestive heart&#xD;
             failure (New York Heart Association &gt;class II), unstable angina, or unstable cardiac&#xD;
             arrhythmia requiring medication&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
&#xD;
          -  History of chronic hepatitis&#xD;
&#xD;
          -  Subject known to have tested positive for HIV&#xD;
&#xD;
          -  Known sensitivity to mammalian derived products&#xD;
&#xD;
          -  Hematological function, as follows:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≤ 1.5 x 109/L for B, P, S and E cohorts&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≤ 3 x 109/L for G cohorts&#xD;
&#xD;
          -  Platelet count ≤ 100 x 109/L&#xD;
&#xD;
          -  Hemoglobin ≤ 9 g/dL&#xD;
&#xD;
          -  Renal function, as follows:&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 50 ml/min using the modified Cockroft-Gault equation&#xD;
&#xD;
          -  Urinary protein quantitative value of &gt; 30 mg or &gt;1+ on dipstick, unless quantitative&#xD;
             protein is &lt; 500 mg in a 24 hour urine sample&#xD;
&#xD;
          -  Hepatic function, as follows:&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &gt; 2.5 x upper limit of normal (ULN) (if liver&#xD;
             metastases are present, ≥ 5 x ULN)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN (if liver metastases are present, ≥ 5 x&#xD;
             ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.0 x ULN (if bone or liver metastases are present, ≥ 5 x ULN)&#xD;
&#xD;
          -  Bilirubin &gt; 2.0 x ULN&#xD;
&#xD;
          -  Prothrombin time (PT) or partial thromboplastin time (PTT) &gt; 1.5 x ULN&#xD;
&#xD;
          -  Treatment with anti-cancer therapy (6 weeks for nitrosoureas and mitomycin C&#xD;
             chemotherapies), antibody therapy, retinoid therapy, or hormonal therapy within 4&#xD;
             weeks before study day 1. Prior and concurrent use of hormone replacement therapy or&#xD;
             the use of gonadotropin-releasing hormone (GnRH) modulators for prostate cancer are&#xD;
             permitted&#xD;
&#xD;
          -  Therapeutic or palliative radiation therapy within 4 weeks before enrollment (subjects&#xD;
             must have resolution of any significant adverse effects from radiation therapy&#xD;
             received prior to 2 weeks before enrollment)&#xD;
&#xD;
          -  Concurrent or prior (within 1 week of study Day 1) anticoagulation therapy, except&#xD;
             low-dose warfarin (≤ 2 mg/day) for prophylaxis against central venous catheter&#xD;
             thrombosis&#xD;
&#xD;
          -  Prior participation in clinical drug trials within 4 weeks before enrollment&#xD;
&#xD;
          -  For subjects receiving erlotinib, the use of ketoconazole, clarithromycin,&#xD;
             voriconazole, troleandomycin, telithromycin, rifabutin, rifapentine, phenytoin,&#xD;
             carbamazepine, phenobarbital and St. John's Wort is prohibited&#xD;
&#xD;
          -  For subjects receiving sorafenib, use of St. John's Wort, rifampin, phenytoin,&#xD;
             carbamazepine, dexamethasone, and phenobarbital (CYP3A inducers) is prohibited&#xD;
&#xD;
          -  Type 1 or 2 diabetics are excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>AMG 479</keyword>
  <keyword>Amgen</keyword>
  <keyword>Oncology</keyword>
  <keyword>Phase 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

